Colao Annamaria, Di Somma Carolina, Cascella Teresa, Pivonello Rosario, Vitale Giovanni, Grasso Ludovica F S, Lombardi Gaetano, Savastano Silvia
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S. Pansini 5, 80131 Naples, Italy.
Eur J Endocrinol. 2008 Oct;159(4):389-97. doi: 10.1530/EJE-08-0201. Epub 2008 Jul 4.
In the general population, low IGF1 has been associated with higher prevalence of cardiovascular disease and mortality.
To investigate the relationships between IGF1 levels, blood pressure (BP), and glucose tolerance (GT).
Four-hundred and four subjects (200 men aged 18-80 years).
personal history of pituitary or cardiovascular diseases; previous or current treatments with drugs interfering with BP, GT, or lipids, corticosteroids (>2 weeks), estrogens, or testosterone (>12 weeks); smoking of >15 cigarettes/day and alcohol abuse (>3 glasses of wine/day).
Two hundred and ninety-six had normal BP (73.3%), 86 had mild (21.3%), and 22 had severe (5.4%) hypertension; 322 had normal GT (NGT (79.7%)), 53 had impaired glucose tolerance (IGT (13.1%)), 29 had diabetes mellitus (7.2%). Normotensive subjects had significantly higher IGF1 levels (0.11+/-0.94 SDS) than those with mild (-0.62+/-1.16 SDS, P<0.0001) or severe (-1.01+/-1.07 SDS, P<0.0001) hypertension. IGF1 SDS (t=-3.41, P=0.001) independently predicted systolic and diastolic BP (t=-2.77, P=0.006) values. NGT subjects had significantly higher IGF1 levels (0.13+/-0.90 SDS) than those with IGT (-0.86+/-1.14 SDS, P<0.0001) or diabetes mellitus (-1.31+/-1.13 SDS, P<0.0001). IGF1 SDS independently predicted fasting glucose (t=-3.49, P=0.0005) and homeostatic model assessment (HOMA)-R (t=-2.15, P=0.033) but not insulin (t=-1.92, P=0.055) and HOMA-beta (t=-0.19, P=0.85).
IGF1 levels in the low normal range are associated with hypertension and diabetes in subjects without pituitary and cardiovascular diseases.
在一般人群中，胰岛素样生长因子1（IGF1）水平较低与心血管疾病患病率和死亡率较高相关。
研究IGF1水平、血压（BP）和糖耐量（GT）之间的关系。
404名受试者（200名年龄在18至80岁之间的男性）。
有垂体或心血管疾病个人史；既往或目前接受过干扰血压、糖耐量或血脂的药物治疗、使用皮质类固醇（超过2周）、雌激素或睾酮（超过12周）；每天吸烟超过15支和酗酒（每天超过3杯葡萄酒）。
296人血压正常（73.3%），86人轻度高血压（21.3%），22人重度高血压（5.4%）；322人糖耐量正常（NGT，79.7%），53人糖耐量受损（IGT，13.1%），29人患有糖尿病（7.2%）。血压正常的受试者IGF1水平（0.11±0.94标准差分值）显著高于轻度高血压患者（-0.62±1.16标准差分值，P<0.0001）或重度高血压患者（-1.01±1.07标准差分值，P<0.0001）。IGF1标准差分值（t=-3.41，P=0.001）可独立预测收缩压和舒张压（t=-2.77，P=0.006）值。糖耐量正常的受试者IGF1水平（0.13±0.90标准差分值）显著高于糖耐量受损患者（-0.86±1.14标准差分值，P<0.0001）或糖尿病患者（-1.31±1.13标准差分值，P<0.0001）。IGF1标准差分值可独立预测空腹血糖（t=-3.49，P=0.0005）和稳态模型评估（HOMA）-胰岛素抵抗指数（t=-2.15，P=0.033），但不能预测胰岛素水平（t=-1.92，P=0.055）和HOMA-β细胞功能指数（t=-0.19，P=0.85）。
在无垂体和心血管疾病的受试者中，低正常范围的IGF1水平与高血压和糖尿病相关。
